Published in Bioorg Med Chem Lett on January 20, 2010
Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients. Hepatology (2009) 3.35
Loss of adenomatous polyposis coli gene function disrupts thymic development. Nat Immunol (2005) 1.66
Characterization of resistance mutations against HCV ketoamide protease inhibitors. Antiviral Res (2007) 1.55
Mutations conferring resistance to SCH6, a novel hepatitis C virus NS3/4A protease inhibitor. Reduced RNA replication fitness and partial rescue by second-site mutations. J Biol Chem (2005) 1.54
Increased intratumoral regulatory T cells are related to intratumoral macrophages and poor prognosis in hepatocellular carcinoma patients. Int J Cancer (2009) 1.53
A requirement for cyclin-dependent kinase 6 in thymocyte development and tumorigenesis. Cancer Res (2009) 1.48
c-Myc mediates pre-TCR-induced proliferation but not developmental progression. Blood (2006) 1.39
A review of HCV protease inhibitors. Curr Opin Investig Drugs (2009) 1.39
Versatile templates for the development of novel kinase inhibitors: Discovery of novel CDK inhibitors. Bioorg Med Chem Lett (2007) 1.10
Fangchinoline induces autophagic cell death via p53/sestrin2/AMPK signalling in human hepatocellular carcinoma cells. Br J Pharmacol (2011) 1.10
Dietary supplementation with white button mushroom enhances natural killer cell activity in C57BL/6 mice. J Nutr (2007) 1.09
Identification of HCV protease inhibitor resistance mutations by selection pressure-based method. Nucleic Acids Res (2009) 1.07
Aromatic-carbohydrate interactions: an NMR and computational study of model systems. Chemistry (2008) 1.06
Analysis of boceprevir resistance associated amino acid variants (RAVs) in two phase 3 boceprevir clinical studies. Virology (2013) 1.02
Molecular epidemiology of human immunodeficiency virus type 1 and hepatitis C virus in former blood donors in central China. AIDS Res Hum Retroviruses (2008) 0.98
Aurora kinase inhibitors based on the imidazo[1,2-a]pyrazine core: fluorine and deuterium incorporation improve oral absorption and exposure. J Med Chem (2010) 0.95
Impact of naturally occurring variants of HCV protease on the binding of different classes of protease inhibitors. Biochemistry (2006) 0.94
Landing of size-selected Agn+ clusters on single crystal TiO2 (110)-(1x1) surfaces at room temperature. J Chem Phys (2005) 0.93
Structure-guided discovery of cyclin-dependent kinase inhibitors. Biopolymers (2008) 0.91
A compound belonging to traditional Chinese medicine improves nocturnal activity in Parkinson's disease. Sleep Med (2011) 0.91
Analysis of HCV resistance mutations during combination therapy with protease inhibitor boceprevir and PEG-IFN alpha-2b using TaqMan mismatch amplification mutation assay. J Virol Methods (2008) 0.90
Discovery of novel hydroxamates as highly potent tumor necrosis factor-alpha converting enzyme inhibitors. Part II: optimization of the S3' pocket. Bioorg Med Chem Lett (2008) 0.90
Analysis of the ERK1,2 transcriptome in mammary epithelial cells. Biochem J (2004) 0.90
Aminoglycoside complexation with a DNA.RNA hybrid duplex: the thermodynamics of recognition and inhibition of RNA processing enzymes. J Am Chem Soc (2003) 0.88
Regioselective cobalt-catalyzed addition of sulfides to unactivated alkenes. J Org Chem (2011) 0.87
The Journey to the Discovery of Boceprevir: an NS3-NS4 HCV protease inhibitor for the treatment of chronic hepatitis C. Prog Med Chem (2010) 0.87
Discovery of potent sulfonamide P4-capped ketoamide second generation inhibitors of hepatitis C virus NS3 serine protease with favorable pharmacokinetic profiles in preclinical species. Bioorg Med Chem (2010) 0.86
Hydroxylated analogues of the orally active broad spectrum antifungal, Sch 51048 (1), and the discovery of posaconazole [Sch 56592; 2 or (S,S)-5]. Bioorg Med Chem Lett (2005) 0.86
White button mushroom enhances maturation of bone marrow-derived dendritic cells and their antigen presenting function in mice. J Nutr (2008) 0.86
Beta-catenin/Tcf determines the outcome of thymic selection in response to alphabetaTCR signaling. J Immunol (2009) 0.86
Factors affecting operating time in laparoscopic anterior resection of rectal cancer. World J Surg Oncol (2014) 0.85
Activation of Notch1 signaling by marrow-derived mesenchymal stem cells through cell-cell contact inhibits proliferation of hepatic stellate cells. Life Sci (2011) 0.85
NP603, a novel and potent inhibitor of FGFR1 tyrosine kinase, inhibits hepatic stellate cell proliferation and ameliorates hepatic fibrosis in rats. Am J Physiol Cell Physiol (2011) 0.85
Mericitabine and ritonavir-boosted danoprevir with or without ribavirin in treatment-naive HCV genotype 1 patients: INFORM-SVR study. Liver Int (2014) 0.85
Identification of PTC725, an orally bioavailable small molecule that selectively targets the hepatitis C Virus NS4B protein. Antimicrob Agents Chemother (2013) 0.85
Amino acid mutations of the infectious clone from Chinese EIAV attenuated vaccine resulted in reversion of virulence. Vaccine (2005) 0.85
In vitro antiviral activity of SCH446211 (SCH6), a novel inhibitor of the hepatitis C virus NS3 serine protease. J Antimicrob Chemother (2006) 0.84
Aporphine alkaloids from the roots of Stephania viridiflavens. Nat Prod Res (2010) 0.84
Conformation constraint of anilides enabling the discovery of tricyclic lactams as potent MK2 non-ATP competitive inhibitors. Bioorg Med Chem Lett (2013) 0.84
Correlation between PAMPA permeability and cellular activities of hepatitis C virus protease inhibitors. Biochem Pharmacol (2007) 0.84
Green tea EGCG suppresses T cell proliferation through impairment of IL-2/IL-2 receptor signaling. Free Radic Biol Med (2009) 0.83
Emerging trends of drug-resistant HIV-1 among drug-treated patients in former blood donors in Hubei, China: a three-year surveillance from 2004 to 2006. Virol Sin (2011) 0.83
Toward the back-up of boceprevir (SCH 503034): discovery of new extended P4-capped ketoamide inhibitors of hepatitis C virus NS3 serine protease with improved potency and pharmacokinetic profiles. J Med Chem (2009) 0.83
Cyclic sulfones as novel P3-caps for hepatitis C virus NS3/4A (HCV NS3/4A) protease inhibitors: synthesis and evaluation of inhibitors with improved potency and pharmacokinetic profiles. J Med Chem (2010) 0.82
Pyrazolo[1,5-a]pyrimidines as orally available inhibitors of cyclin-dependent kinase 2. Bioorg Med Chem Lett (2007) 0.82
Structure-activity relationship (SAR) optimization of 6-(indol-2-yl)pyridine-3-sulfonamides: identification of potent, selective, and orally bioavailable small molecules targeting hepatitis C (HCV) NS4B. J Med Chem (2013) 0.82
Discovery of SCH446211 (SCH6): a new ketoamide inhibitor of the HCV NS3 serine protease and HCV subgenomic RNA replication. J Med Chem (2006) 0.82
Synthesis of new 4,5-dihydrofuranoindoles and their evaluation as HCV NS5B polymerase inhibitors. Org Lett (2012) 0.82
Toward second generation hepatitis C virus NS3 serine protease inhibitors: discovery of novel P4 modified analogues with improved potency and pharmacokinetic profile. J Med Chem (2009) 0.82
A conservative domain shared by HIV gp120 and EIAV gp90: implications for HIV vaccine design. AIDS Res Hum Retroviruses (2005) 0.82
A novel class of highly potent irreversible hepatitis C virus NS5B polymerase inhibitors. J Med Chem (2012) 0.82
Novel dipeptide macrocycles from 4-oxo, -thio, and -amino-substituted proline derivatives. J Org Chem (2002) 0.81
Discovery and structure-activity relationship of P1-P3 ketoamide derived macrocyclic inhibitors of hepatitis C virus NS3 protease. J Med Chem (2009) 0.81
Evaluation of cancer dependence and druggability of PRP4 kinase using cellular, biochemical, and structural approaches. J Biol Chem (2013) 0.81
The discovery of tropane derivatives as nociceptin receptor ligands for the management of cough and anxiety. Bioorg Med Chem Lett (2009) 0.81
A novel HCV NS3 protease mutation selected by combination treatment of the protease inhibitor boceprevir and NS5B polymerase inhibitors. Antiviral Res (2009) 0.81
Potent ketoamide inhibitors of HCV NS3 protease derived from quaternized P1 groups. Bioorg Med Chem Lett (2010) 0.80
Application of ring-closing metathesis for the synthesis of macrocyclic peptidomimetics as inhibitors of HCV NS3 protease. Org Lett (2007) 0.80
Structure-activity relationship (SAR) development and discovery of potent indole-based inhibitors of the hepatitis C virus (HCV) NS5B polymerase. J Med Chem (2012) 0.80
Second-generation highly potent and selective inhibitors of the hepatitis C virus NS3 serine protease. J Med Chem (2009) 0.80
P2-P4 macrocyclic inhibitors of hepatitis C virus NS3-4A serine protease. Bioorg Med Chem Lett (2006) 0.80